Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

125.83 +0.10 (+0.08%)
Official Closing Price Updated: 6:30 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
46 47 Next >
A Look Into Abbott Laboratories Inc's Price Over Earnings
Via Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
How Is The Market Feeling About Abbott Laboratories?
Via Benzinga
3 Magnificent Dividend Stocks to Buy in October
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Investors can find market-trouncing blue chip stocks in the healthcare industry. 
Via The Motley Fool
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Navigating 6 Analyst Ratings For Abbott Laboratories
Via Benzinga
Why ABBOTT LABORATORIES (NYSE:ABT) should be investigated by quality investors.
Is ABBOTT LABORATORIES (NYSE:ABT) a Strong Candidate for Quality Investing? 
Via Chartmill
Down More Than 50%, Is DexCom Stock a Bargain Now?
Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market. 
Via The Motley Fool
2 Excellent Dividend Stocks to Buy With Less Than $200
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years. 
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
These dividend players could lift your portfolio no matter what the market is doing. 
Via The Motley Fool
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation. 
Via Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates
Investors are anticipating the first cut to the federal funds rate in over four years at the September FOMC meeting. The market is divided on the magnitude of the cut, which could trigger significant... 
Via Benzinga
Topics Economy Stocks
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
The dividend growth powerhouse is turning the corner. 
Via The Motley Fool
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
The company continues to flex its innovative muscles. 
Via The Motley Fool
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold
These stocks have increased their payouts for decades. 
Via The Motley Fool
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
You can take these dividends straight to the bank. 
Via The Motley Fool
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases 
Via MarketBeat
Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System
Abbott recalls some FreeStyle Libre 3 sensors due to incorrect glucose readings, risking severe health issues. 
Via Benzinga
Topics Product Recall
Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device
The companies are now duking it out for a new population of CGM users. 
Via Investor's Business Daily
Patchy But Still Bullish
Two weeks ago we turned to a more bullish stance, which has proved to be correct, though we still await the explosive movement out of these consolidations. 
Via Talk Markets
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
These three have secure core businesses, plus multiple paths to grow. 
Via The Motley Fool
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a prescription. Designed for people with Type 2 diabetes and prediabetes, Stelo... 
Via Benzinga
Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?
The company is upbeat on its upcoming Stelo launch. The CGM is geared to people who don't use insulin. 
Via Investor's Business Daily
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
This MedTech leader is back on track with profitable growth. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.